Last reviewed · How we verify

NCT04190290: ANIPAP

Anorexia Nervosa Inpatient Physiotherapy Adapted Program

Completed Phase 4 Last updated 23 May 2022
What this trial tests

Phase 4 trial testing Physiotherapy Adapted Program in Anorexia Nervosa in 26 participants. Completed in 1 May 2022.

Timeline
11 April 2018
Primary endpoint
15 January 2021
1 May 2022

Quick facts

Lead sponsorUniversidad de Murcia
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment26
Start date11 April 2018
Primary completion15 January 2021
Estimated completion1 May 2022
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Universidad de Murcia — full company profile →

Who can join

12 and older, female only, with Anorexia Nervosa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anorexia nervosa (AN) is a psychiatric pathology with several somatics consequences that increase the vital risk. The prevalence in AN is between 0.9-3% and AN has the most elevated mortality in the psychiatric pathologies (10% in the hospitalized patients). The collateral effects by several undernourishment has been studied but the autonomy and muscle strength research is insufficient. Physiotherapy research study body image, basic body awareness therapy, relaxation and quality of life.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anorexia Nervosa

Currently open trials in the same condition.

Other Universidad de Murcia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04190290.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing